SAN ANTONIO, Texas, Sept. 23, 2015 /PRNewswire/ -- For immediate release: Today Aperion Biologics, Inc. announces that it has filed an Offering Statement on Form 1-A with the Securities and Exchange Commission (SEC) to raise $20 million in a public offering of common stock under SEC Regulation A. The offering will be conducted on a best-efforts basis by WR Hambrecht + Co. as the sole underwriter. The number of shares to be offered and the price range for the proposed offering have not yet been determined.
Regulation A, an exemption from registration for smaller issuers of securities under SEC rules, was recently updated and expanded by the SEC, as mandated by the Jumpstart Our Business Startups (JOBS) Act. The new rules are often referred to as Regulation A+ and are designed to facilitate smaller companies' access to capital and provide investors with more investment choices. WR Hambrecht + Co, like Hambrecht & Quist, the storied boutique investment bank that came before it, is at the vanguard of this new trend to provide growth capital to early stage companies.
About Aperion Biologics
Aperion Biologics, Inc. is a commercial-stage medical device company addressing the significant need for an alternative to human-based sources of tissues to be used in surgical procedures. Its lead product, the Z-Lig®, is produced by a patent-protected process for porcine tendons and its safety and performance was demonstrated in clinical trials in the U.S., Europe and South Africa. The Company received a CE Mark (the regulatory permission to market the product in Europe) for use initially as a knee joint anterior cruciate ligament replacement in revision and multiligament procedures, which allows the Company to distribute the Z-Lig in any market which recognizes this approval. The Company also has FDA unconditional approval to conduct a pivotal clinical trial in the United States for its Z-Lig product.
About WR Hambrecht + Co
WR Hambrecht + Co focuses on raising growth capital for a variety of different enterprises, including life sciences companies. Like its predecessor firm, Hambrecht & Quist, WRH+Co, seeks to identify high prospect growth-stage companies, and then enable access to the capital necessary to fund development, marketing and infrastructure so that these companies can achieve their full potential. WRH+Co's Regulation A+ strategy is a continuation of Bill Hambrecht's legacy of conducting small public offerings for what were once considered high-risk start-ups that are now household names and Fortune 500 companies.
The offering is being made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the Securities and Exchange Commission but has not yet become qualified. You may obtain a copy of the most recent version of the preliminary offering circular with the following link: http://www.sec.gov/Archives/edgar/data/1439026/000092963815000751/a69629_partsiiandiii.htm These securities may not be sold nor may offers to buy be accepted prior to the time the offering statement is qualified. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
No money or other consideration is being solicited in connection this press release, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement on Form 1-A is qualified pursuant to Regulation A of the Securities Act of 1933, as amended, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. Any person's indication of interest involves no obligation or commitment of any kind.
SOURCE Aperion Biologics, Inc.